Logo

Dyadic Pockets $12.6M in Private Stock Placement to Fund Tech Expansion

Nov 20, 2006
NEW YORK (GenomeWeb News) — Enzyme developer Dyadic International today said it has generated around $12.6 million in a private stock placement.
 
Dyadic said it will use roughly $12.3 million of the placement to expand its C1 Host Technology, which is used in the production of biomass production, and potentially in human antibody and therapeutic protein production.
 
The company also plans to use some funds to speed up the launch of new enzyme products, R&D and marketing.
 
The company said it has placed 2.7 million shares of common stock at $4.68 per share, and has granted warrants to buy up to 557,000 more shares.
 
The warrants may be exercised 181 days after the issue date and will expire three years after that at an exercise price at $6.33.

Breaking News
The Scan

Plan Rebuffed

The Associated Press reports China has rejected the World Health Organization's proposal to include the lab-leak theory in the next phase of its investigation into the origins of SARS-CoV-2.

Opossum Change

Researchers from Riken have used CRISPR to edit marsupial genomes, as Technology Review reports.

In the Ice

Cosmos magazine reports that researchers have uncovered more than two dozen ancient viruses in a Tibetan glacier.

Nature Papers Present Method to Uncover Differential RNA Modifications, Neutrophils in Innate Immune Response

In Nature this week: computational approach to identifying differential RNA modifications, and more.